This webinar brings together a cohort of distinguished researchers who have dedicated their efforts to evolving cancer treatment paradigms. Dr. Evanthia Galanis, the Group Chair of the Alliance and Sandra J. Schulze Professor of Novel Therapeutics at Mayo Clinic, emphasized the significance of translating trial results into clinical practice. She notes that the expert panel will delve into how these findings could reshape the current therapeutic standards, including precision medicine approaches tailored to tumor biology and patient genetics.

Among the marquee studies to be discussed is the Alliance A091802 trial, led by Dr. Dan Zanberg from UPMC Cancer Center, investigating the efficacy of combining avelumab with cetuximab versus avelumab alone in advanced cutaneous squamous cell carcinoma. This phase II randomized controlled trial addresses the immunotherapeutic synergies that target tumor immune evasion mechanisms, suggesting potential paradigms for enhancing checkpoint inhibitor efficacy through combinatorial antibody regimens.

Dietary influences on tumor progression represent another critical domain analyzed in the Alliance CALGB/SWOG 80702 study. Presented by Dr. Sara Char of Dana Farber Cancer Institute, this research explores the empirical dietary inflammatory pattern’s association with survival outcomes in stage III colon cancer patients. By quantifying pro-inflammatory dietary components and correlating them with systemic inflammatory markers and recurrence rates, this work underscores the complex nexus between nutrition, inflammation, and tumor microenvironment modulation.

Adjuvant immunotherapy’s role in genetically defined colorectal cancer subsets is the focus of the Alliance A021502-ATOMIC trial, led by Dr. Frank Sinicrope of Mayo Clinic. This phase III randomized study assesses whether the addition of atezolizumab to standard chemotherapy improves outcomes in patients with stage III colorectal cancer exhibiting deficient DNA mismatch repair (dMMR). The rationale is grounded in exploiting the heightened immunogenicity associated with dMMR tumors, potentially potentiating immune checkpoint inhibitors to eradicate minimal residual disease post-surgery.

Addressing chemotherapy-induced peripheral neuropathy (CIPN), a major dose-limiting toxicity of oxaliplatin, the Alliance A221805 phase II study highlights pharmacological prevention strategies. Dr. Ellen Smith of the University of Alabama School of Nursing reviews the trial evaluating duloxetine — a serotonin-norepinephrine reuptake inhibitor — for its efficacy in mitigating neuropathic symptoms. This double-blind, placebo-controlled investigation offers insights into optimizing supportive care interventions to preserve patients’ quality of life during cytotoxic chemotherapy.

Renal cell carcinoma management benefits from the Alliance A031704 trial findings, presented by Dr. Tian Zhang from University of Texas Southwestern Medical Center. This phase III PDIGREE study analyzes the combinatorial use of ipilimumab and nivolumab as frontline treatment for metastatic clear cell renal carcinoma. By focusing on the immune checkpoint blockade targeting CTLA-4 and PD-1 pathways, the study reveals how dynamic immune modulation can influence tumor regression rates and progression-free survival in a notoriously treatment-resistant malignancy.

The Alliance for Clinical Trials in Oncology serves as a national leader in orchestrating multi-institutional research collaborations, uniting over 25,000 cancer clinicians across 115 primary institutions and 1,400 affiliates throughout North America. Operating under the auspices of the National Clinical Trials Network and as a major research node within the NCI Community Oncology Research Program, the Alliance drives rigorously designed investigations that inform FDA approvals, clinical guidelines, and standard-of-care practices.

The robust participation and sample collection infrastructure underpinning Alliance studies are unprecedented, with more than 40,000 individuals enrolled to date and a biospecimen repository exceeding 1.5 million samples accumulated over three decades. This vast biobank, coupled with rich clinical annotation, facilitates translational research endeavors that seek biomarkers for cancer prognosis, therapy response prediction, and resistance mechanisms, thereby accelerating personalized medicine.

Collectively, the findings exhibited during the upcoming webinar are anticipated to influence oncologists’ treatment decisions globally. By integrating immunotherapy, nutrition science, pharmacologic neuropathy prevention, and molecular genetic stratification, the Alliance’s research portfolio exemplifies a holistic approach to cancer care. These advancements highlight the evolving complexity of malignancies and the necessity for interdisciplinary collaboration to improve patient survival and wellbeing.

The webinar also emphasizes the importance of disseminating scientific knowledge beyond specialists, aiming to empower patients and caregivers with an understanding of evolving therapeutics and clinical trial outcomes. Such transparency fosters informed decision-making and engagement in cutting-edge experimental treatments, essential components of personalized oncology.

As the oncology community prepares for this dissemination of innovative trial results, the Alliance continues to solidify its role as a transformative force in cancer research. The organization’s endeavors not only enhance scientific comprehension but also underscore the critical synergy between clinical investigation and patient-centered care, paving the way for future breakthroughs.

In summary, the September 29 webinar by the Alliance for Clinical Trials in Oncology promises to be a landmark event, shedding light on novel therapeutic strategies, trial methodologies, and translational research milestones. Through these endeavors, the oncology field moves closer toward the overarching goal of rendering cancer a manageable, if not curable, disease across diverse populations.

Subject of Research: Clinical Trial Outcomes in Oncology Focusing on Colorectal, Squamous Cell, and Renal Cell Cancers

Article Title: Alliance for Clinical Trials in Oncology to Present Groundbreaking Findings from 2025 ASCO Annual Meeting

News Publication Date: September 29, 2025

Web References:

• Alliance for Clinical Trials in Oncology Official Site
• Registration for the Webinar
• ASCO trial abstracts linked in the original announcement (e.g., Alliance A091802, A021502, etc.)

Keywords: Oncology, Cancer Research, Clinical Trials, Colorectal Cancer, Squamous Cell Carcinoma, Renal Cell Carcinoma, Immunotherapy, Chemotherapy, Peripheral Neuropathy, Cancer Genetics, DNA Mismatch Repair, Immune Checkpoint Inhibitors

CAR T cell therapy has revolutionized hematologic oncology with remarkable success against blood cancers by redirecting immune cells to target malignant cells specifically. However, solid tumors such as glioblastoma have historically resisted such approaches due to their unique microenvironment and immune evasive mechanisms. The Penn team’s breakthrough lies in their dual-targeted CAR T cells, designed to address this challenge by simultaneously engaging two proteins frequently overexpressed in GBM: epidermal growth factor receptor (EGFR) and interleukin-13 receptor alpha 2 (IL13Rα2). This bivalent targeting increases the therapy’s precision and potency, while delivery directly into the cerebrospinal fluid enhances tumor site accessibility.

The clinical trial recruited 18 patients suffering from recurrent GBM, a notoriously resilient cancer that typically recurs within months of standard surgical and adjuvant therapies. All patients underwent maximal tumor resection before receiving an intracerebroventricular infusion of the dual-targeted CAR T cells. Remarkably, among those with measurable tumors post-surgery, nearly two-thirds (62 percent) experienced significant tumor reduction following treatment. While the reduction was often transient, the therapy altered the disease’s natural trajectory, translating into meaningful periods of progression-free survival and quality of life improvements.

This dual-pronged CAR T cell injection exhibited durability beyond immediate effects, with immune surveillance markers detected in cerebrospinal fluid samples months after infusion. In some instances, CAR T cells remained active for over a year, a testament to the persistent immune engagement against residual tumor cells. One patient, notably, displayed extensive immune cell infiltration—comprised of T cells and macrophages—within tumor tissue excised after relapse, confirming the immune system’s ongoing response driven by the therapy.

These early clinical observations not only reinforce the therapeutic potential of CAR T cells in solid tumor brain neoplasms but also challenge the longstanding assumption that the brain’s immune-privileged status precludes effective immunotherapy. Delivery via cerebrospinal fluid appears to circumvent traditional obstacles like the blood-brain barrier, allowing engineered immune cells direct access to tumor sites. This modality may herald a paradigm shift in treating central nervous system malignancies.

Safety considerations, paramount in any novel therapy, were rigorously monitored, revealing manageable neurotoxicity in over half of the patients at grade 3 severity. Importantly, these adverse events aligned with known side effects of existing FDA-approved CAR T therapies and were effectively managed without introducing unexpected complications. This points to the feasibility of administering such therapies within a controlled clinical setting, balancing efficacy with patient safety.

The study’s findings carry significant implications for the future of GBM treatment. The median survival for patients following recurrence traditionally falls between 6 to 10 months, with few effective options available beyond palliative care. Yet, in this trial, some patients surpassed the one-year survival benchmark, including one individual who maintained stable disease for more than 16 months despite initial advanced tumor spread and aggressive progression. These outcomes advocate for the expansion of clinical investigations, particularly focusing on the application of dual-target CAR T therapy earlier in the disease course.

Researchers aim to optimize therapeutic efficacy by exploring repeat dosing strategies in subsequent trial phases. The current study administered a single infusion, but ongoing efforts seek to determine whether multiple administrations can sustain or enhance tumor control over longer periods. This approach could be transformative, converting temporary remission into durable responses or even long-term remission.

Beyond glioblastoma, this dual-target CAR T platform serves as a proof of concept for multi-antigen targeting in challenging solid tumors, potentially extending to other refractory cancers exhibiting heterogeneous antigen expression. By broadening the immune system’s attack scope, this strategy counters tumor escape pathways that rely on downregulating or mutating single antigen targets.

Academically, this research signifies a milestone in onco-immunology, integrating cutting-edge gene editing, neuro-oncology, and immunotherapy. The work stems from the laboratory of Dr. Donald M. O’Rourke, whose pioneering efforts in neuroimmunotherapy have defined new frontiers in treating brain cancers. Collaboratively, the study aligns with Penn’s commitment to translating laboratory innovations into clinical realities, driving hope for patients confronting otherwise dismal prognoses.

The trial’s momentum, bolstered by support from Kite, a Gilead Company, alongside the Abramson Cancer Center and philanthropic initiatives, underscores the critical role of interdisciplinary and multi-sector partnerships in achieving breakthroughs. As the therapy advances toward trials in newly diagnosed GBM patients, the oncology community eagerly anticipates whether earlier intervention will further enhance outcomes and redefine standards of care for this devastating disease.

In summary, the intracerebroventricular bivalent CAR T cell therapy represents a pioneering stride in confronting recurrent glioblastoma, demonstrating both tumor regression and manageable safety profiles. While further research and larger clinical trials are essential to confirm and broaden these findings, the current data illuminate a promising path towards harnessing the immune system’s power against one of the most formidable cancers afflicting the brain.

Subject of Research: Dual-target CAR T cell therapy for recurrent glioblastoma

Article Title: Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial

News Publication Date: June 1, 2025

Web References:
https://www.pennmedicine.org/treatments/car-t-cell-therapy
https://www.asco.org/annual-meeting
https://www.nature.com/articles/s41591-025-03745-0
https://clinicaltrials.gov/study/NCT06973096

References:
Bagley, S. et al. Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial. Nature Medicine. 2025. DOI: 10.1038/s41591-025-03745-0.

Keywords: Glioblastoma, Brain cancer, CAR T cell therapy, Cancer immunotherapy, Dual-target CAR T, EGFR, IL13Rα2, Immunotherapy, Neuro-oncology, Tumor microenvironment

Colon cancer remains the third most prevalent malignancy in the United States, often detected and managed through established screening protocols; however, advancements in adjuvant therapies have been incremental, particularly for stage 3 disease characterized by nodal involvement. This stage traditionally receives a six-month course of chemotherapy post-surgery, yet nearly one-third of these patients experience tumor relapse. These sobering statistics underscore the urgent need for more efficacious treatments. The recent study addresses this gap by harnessing the immune system’s power to augment standard chemotherapy.

The trial enrolled 712 patients diagnosed with stage 3 colon cancer exhibiting deficient mismatch repair mechanisms, a mutation profile found in approximately 15% of colon cancer cases. dMMR tumors fail to repair nucleotide mispairings during DNA replication, leading to a hypermutated state that paradoxically renders these cancers less responsive to conventional chemotherapy. The research team utilized atezolizumab, an immune checkpoint inhibitor targeting the PD-L1 pathway, alongside chemotherapy to invigorate the patient’s immune response directed against residual cancer cells post-surgery.

Patients received a combined regimen of chemotherapy and atezolizumab over the initial six months, followed by an additional six months of atezolizumab monotherapy. This sequential administration was designed to not only debulk microscopic disease with cytotoxic chemotherapy but also sustain immune-mediated tumor surveillance. The immunotherapy leverages the immune checkpoint blockade to unleash T-cell activity, overcoming tumor-induced immunosuppression, particularly crucial in dMMR tumors laden with infiltrating inflammatory cells responsive to immune modulation.

Immunohistochemical analyses from prior studies by Dr. Frank Sinicrope’s group revealed that dMMR colon cancers exhibit significant infiltration by immune cells expressing checkpoint molecules such as PD-L1, providing a rational basis for the application of checkpoint inhibitors. These biomarkers suggested that immune evasion mechanisms were pivotal in enabling cancer persistence, advocating for immunotherapy’s role in this context. The trial’s success empirically validates this hypothesis, aligning molecular biology insights with clinical outcomes.

Until now, adjuvant therapy regimens have homogenized treatment across genetic subtypes, overlooking the heterogeneity in tumor biology that profoundly impacts therapeutic efficacy. By tailoring treatment based on the molecular hallmark of mismatch repair deficiency, this study exemplifies precision oncology’s promise. The magnitude of benefit, halving the risk of recurrence and death, signifies a paradigm shift, particularly given the historically limited options for dMMR colon cancer patients who derive less benefit from chemotherapy alone.

Notably, the trial population included individuals with Lynch syndrome, the predominant hereditary colon cancer syndrome characterized by germline mutations in mismatch repair genes. Lynch syndrome patients are predisposed to dMMR tumors, making them prime candidates for benefit from this novel therapeutic approach. This inclusion underscores the translational potential of the findings, extending impact beyond sporadic colon cancer to hereditary cancer syndromes.

The researchers plan to submit their findings to the National Comprehensive Cancer Network (NCCN) to advocate for incorporating immunotherapy combined with chemotherapy as the new adjuvant standard for stage 3 dMMR colon cancer. Adoption of this recommendation would influence clinical guidelines across leading cancer centers, facilitating broad access to this breakthrough treatment, thereby improving survival outcomes on a population scale.

Dr. Sinicrope emphasizes that early intervention with immunotherapy at this stage of disease alters the natural history of colon cancer, offering renewed hope to patients who previously faced high rates of recurrence. The dual modality approach targets both the tumor cells and the immune microenvironment, representing an integrated strategy that not only attacks residual disease but also empowers the immune system to sustain vigilance against relapse.

This study exemplifies how understanding tumor immunobiology can lead to innovative treatment strategies. The employment of atezolizumab capitalizes on the unique immunogenic landscape of dMMR cancers, characterized by high mutation load and active immune infiltration, making them exquisitely sensitive to checkpoint blockade. This synergy between immune activation and cytotoxic therapy orchestrates a multipronged offensive against cancer.

While the study primarily focused on stage 3 colon cancer, the implications resonate throughout oncology, highlighting the importance of genetic and immunologic tumor profiling in treatment decisions. Future research may explore broader applications in other stages or cancer types with similar molecular features, potentially expanding the benefit of immunotherapy beyond currently approved indications.

The success of this trial further underscores the pivotal role of comprehensive cancer centers like Mayo Clinic in advancing translational research from bench to bedside. Through rigorous molecular characterization and robust clinical trial infrastructure, the Mayo Clinic Comprehensive Cancer Center continues to lead discoveries that redefine cancer care paradigms and improve patient survival worldwide.

In summary, the addition of atezolizumab immunotherapy to chemotherapy post-surgery for patients with stage 3 dMMR colon cancer constitutes a monumental advancement, halving recurrence and mortality rates. This tailored approach heralds precision medicine’s arrival in routine oncology practice and portends improved prognoses for a patient population historically underserved by conventional therapies.

Subject of Research: Treatment advancement in stage 3 dMMR colon cancer through integration of immunotherapy with chemotherapy.

Article Title: Immunotherapy Plus Chemotherapy Halves Recurrence and Mortality in Stage 3 dMMR Colon Cancer: A Paradigm Shift in Adjuvant Treatment.

News Publication Date: 2025 (Presented at 2025 ASCO Annual Meeting).

Web References:

• Mayo Clinic Colon Cancer Overview: https://www.mayoclinic.org/diseases-conditions/colon-cancer/symptoms-causes/syc-20353669
• Mayo Clinic Comprehensive Cancer Center: https://www.mayoclinic.org/departments-centers/mayo-clinic-cancer-center
• 2025 American Society of Clinical Oncology Annual Meeting: https://www.asco.org/annual-meeting
• Lynch Syndrome Information: https://www.mayoclinic.org/diseases-conditions/lynch-syndrome/symptoms-causes/syc-20374714
• National Comprehensive Cancer Network: https://www.nccn.org

Keywords: Colon cancer, deficient DNA mismatch repair (dMMR), immunotherapy, atezolizumab, chemotherapy, stage 3 colon cancer, immune checkpoint inhibitors, Lynch syndrome, adjuvant therapy, cancer recurrence, survival improvement, precision oncology.

Cutaneous squamous cell carcinoma represents one of the most prevalent skin cancers in the United States, with an estimated incidence ranging from 700,000 to 1 million new cases annually. While the majority of these cases respond well to existing treatment modalities, a stubborn subset—approximately 12,500 patients each year—progresses to regional lymph node involvement or distant metastases, leading to a grim prognosis with an annual death toll estimated between 2,000 and 8,000 individuals. These advanced cases present significant clinical challenges due to the aggressive nature of the disease and limited effective options after initial therapies fail.

Immune checkpoint inhibitors such as cemiplimab and pembrolizumab have reshaped the therapeutic landscape for advanced cSCC by targeting the PD-1 or PD-L1 axis, offering patients improved outcomes. However, despite this progress, a substantial proportion of patients experience disease progression during or after checkpoint blockade. The trial conducted by the Alliance aimed to explore whether adding cetuximab—a monoclonal antibody directed against the epidermal growth factor receptor (EGFR)—to avelumab could potentiate antitumor immunity through complementary mechanisms, thereby enhancing clinical benefit.

Cetuximab’s role in this combination is particularly innovative. Beyond inhibiting EGFR signaling, cetuximab is an IgG1 monoclonal antibody capable of engaging innate immunity via antibody-dependent cellular cytotoxicity (ADCC). By recruiting immune effector cells such as natural killer cells and macrophages, cetuximab may amplify immune-mediated tumor cell destruction. The rationale for combining cetuximab with avelumab, an anti-PD-L1 agent, lies in the potential synergy between checkpoint blockade and enhanced innate immune activation, which preclinical models suggest could overcome resistance mechanisms prevalent in advanced cSCC.

The Alliance A091802 study randomized 60 patients diagnosed with advanced cSCC to receive either avelumab alone or avelumab combined with cetuximab, both administered biweekly. Patients who experienced progression on avelumab monotherapy were permitted to cross over to the combination arm, allowing the investigators to assess efficacy in both frontline and immunotherapy refractory contexts. The median age of study participants was 72 years, with most patients being white males. Importantly, the majority of tumors originated in the head and neck region, reflecting the common anatomical distribution of aggressive cSCC.

The trial’s findings were striking. The median progression-free survival for patients receiving the combination therapy reached 11.1 months, a significant improvement compared to just 3.0 months for those on avelumab monotherapy. This translated to a hazard ratio of 0.48, indicating nearly a 52% reduction in the risk of disease progression or death with dual therapy. Notably, the confidence interval for median PFS in the combination arm extended beyond the study follow-up period (not reached), suggesting durable disease control in many patients.

Among patients who crossed over from avelumab alone to the combination regimen upon progression, median progression-free survival post-crossover was similarly prolonged, at 11.3 months. These data underscore the potential value of the combination even in cases where initial monotherapy with checkpoint inhibition had failed. Overall survival data, while not yet mature, indicated a favorable trend for the combination arm, though differences did not reach statistical significance, likely due to limited events and sample size.

The confirmed objective response rates were 27.6% for the combination therapy group versus 21.4% for those treated with avelumab alone. While modest in absolute terms, these responses were clinically meaningful and complemented the PFS findings, supporting the hypothesis that dual targeting can elicit enhanced antitumor effects. Tumor PD-L1 expression, observed in approximately 75% of patients, was balanced between groups and continues to be explored as a possible biomarker predicting response to checkpoint blockade.

Safety profiles, a critical consideration in combination regimens, revealed that treatment-related adverse events were more frequent with the addition of cetuximab. Ninety-three percent of patients on avelumab plus cetuximab experienced side effects, compared to 78.6% in the monotherapy group. Grade 3 or higher toxicities also increased, observed in 48.3% versus 21.5%, respectively. The predominant serious adverse events in the combination cohort were rash and infusion-related reactions, each affecting about one in five patients. Importantly, there were no treatment-related deaths or unexpected toxicities, and adverse events were manageable with appropriate medical intervention.

From a mechanistic standpoint, the study validates the concept that integral targeting of both adaptive and innate immune pathways can provide enhanced and durable tumor control. While avelumab inhibits the PD-L1 protein that cancer cells exploit to evade T cell-mediated immunity, cetuximab’s direct engagement with EGFR and activation of ADCC recruits immune cells capable of immediate cytotoxic action. This dual-pronged approach may disrupt tumor immune evasion more effectively than either strategy alone.

The trial’s design and implementation were enabled through a partnership between the National Cancer Institute-funded Alliance for Clinical Trials in Oncology and EMD Serono, which provided avelumab and trial support. This collaboration exemplifies the critical role of public-private partnerships in advancing cancer therapeutics through rigorous clinical investigation. The Alliance’s expansive network, comprising over 25,000 specialists and 115 institutions, facilitated comprehensive patient enrollment across the United States, ensuring robust and generalizable data.

Looking ahead, these encouraging findings open avenues for further exploration of combination immunotherapies in cSCC and potentially other squamous cell malignancies. They also raise pertinent questions about optimal sequencing, patient selection, and biomarkers predictive of response or resistance. Moreover, future studies might investigate whether integrating other agents that modulate the tumor microenvironment or innate immunity could magnify the benefits observed here.

In conclusion, the Alliance A091802 trial marks a pivotal step forward in the management of advanced cutaneous squamous cell carcinoma. By harnessing the synergy between checkpoint inhibition and EGFR-targeted immunologic activation, the study provides a promising therapeutic avenue that could improve outcomes for patients facing this challenging disease. As oncology continues to evolve towards more personalized and mechanistically informed therapies, such integrative approaches exemplify the future of cancer care.

Subject of Research: Advanced cutaneous squamous cell carcinoma treatment with combination immunotherapy

Article Title: Phase II Trial Demonstrates Enhanced Progression-Free Survival with Avelumab plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma

News Publication Date: May 31, 2025

Web References:

• Journal of Clinical Oncology article
• ClinicalTrials.gov NCT03944941

References: Alliance A091802 clinical trial data presented at 2025 ASCO Annual Meeting

Keywords: Skin cancer, cutaneous squamous cell carcinoma, immunotherapy, checkpoint inhibitors, avelumab, cetuximab, EGFR, antibody-dependent cellular cytotoxicity, progression-free survival, clinical trial

Cutaneous squamous cell carcinoma is among the most common forms of skin cancer, with approximately 1.8 million new cases diagnosed annually in the United States. Although the majority of cSCC cases are detected early and resolved with straightforward surgical interventions, a small but clinically urgent subset of patients develop either locally advanced disease that is unresectable or metastatic cancer. At this advanced stage, therapeutic options have historically been limited, and the prognosis remains poor despite systemic therapies. It is within this context that the new trial’s results offer a beacon of hope.

The Alliance A091802 trial, sponsored by the National Cancer Institute’s National Clinical Trials Network and developed collaboratively by researchers across the United States, enrolled 57 patients with advanced cSCC. Patients were randomly assigned to receive either the combination of avelumab plus cetuximab or avelumab monotherapy. Importantly, the trial employed a crossover design that allowed patients initially treated with avelumab alone whose disease progressed to subsequently receive the combination therapy, enabling nuanced insights into therapeutic sequencing.

Avelumab functions as an immune checkpoint inhibitor specifically targeting the protein programmed death-ligand 1 (PD-L1) expressed on tumor cells. By binding PD-L1, avelumab prevents it from engaging PD-1 receptors on T cells, a mechanism that tumors exploit to evade immune destruction. This blockade releases inhibitory signals—or "immune brakes"—restoring T cell activity against the tumor. Although anti-PD-1/PD-L1 therapies have transformed cancer treatment landscapes, their efficacy in advanced cSCC remains variable, underscoring the need for improved combinations.

Cetuximab, on the other hand, is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), a tyrosine kinase receptor frequently overexpressed in cSCC cells. EGFR activation fuels tumor cell proliferation, survival, and metastatic potential. Beyond direct tumor targeting, cetuximab has immune-modulatory effects, enhancing natural killer (NK) cell-mediated cytotoxicity and promoting dendritic cell activation, both critical in orchestrating a robust anti-tumor immune response. Prior seminal research by Dr. Robert Ferris and colleagues at UPMC Hillman elucidated cetuximab’s role in modulating these immune effector pathways.

Dr. Zandberg explained the strategic rationale behind this combination approach: by pairing avelumab’s release of immune brakes with cetuximab’s immune activation—the metaphorical “accelerator pedal”—the immune system’s attack on tumor cells can be synergistically amplified. Rather than additive effects, the combined therapy was hypothesized and now demonstrated to invoke synergistic immunological mechanisms that translate into substantial clinical benefit.

The trial’s primary endpoint, progression-free survival (PFS), was dramatically improved with the combination regimen. Patients receiving avelumab plus cetuximab had a median PFS of 11 months, nearly quadrupling the 3-month median observed in those treated with avelumab alone. This striking enhancement in disease control highlights the potential of dual immune checkpoint and targeted antibody therapy in transforming outcomes for advanced cSCC patients, a group for whom survival extensions have long been elusive.

Despite these positive signals, the combination of avelumab and cetuximab is not yet recommended as the new standard of care, largely because it was compared to avelumab monotherapy in the trial, while two other anti-PD-1/PD-L1 agents—cemiplimab and pembrolizumab—have since gained FDA approvals based on superior efficacy profiles in cSCC. Nevertheless, this trial is the first prospective randomized study directly contrasting cetuximab plus PD-1/PD-L1 blockade against PD-1/PD-L1 blockade alone in cSCC or related head and neck cancers. Its findings pave the way for future investigations testing cetuximab in combination with the existing first-line immunotherapies.

Interestingly, patients in the crossover arm—who initially received avelumab alone and switched to the combined regimen upon disease progression—exhibited progression-free survival comparable to those treated with the combination upfront. This finding is clinically significant, as current treatments typically transition patients who fail anti-PD-1 monotherapy to chemotherapy or cetuximab alone. The data suggest that continuing checkpoint inhibition while adding cetuximab may produce enhanced outcomes, advocating for rethinking salvage therapy strategies in this population.

These results underscore the urgent need for innovative immunotherapy combinations and the value of understanding the interplay between antibody-dependent cellular cytotoxicity and immune checkpoint modulation. By intricately harnessing both direct tumor targeting and immune system activation, the dual approach exemplifies a promising paradigm shift in treating immune-evasive skin cancers.

The study was supported through a robust collaboration facilitated by the National Cancer Institute and the Alliance for Clinical Trials in Oncology, with additional drug supply from EMD Serono. UPMC Hillman Cancer Center served as the primary site for patient enrollment, reflecting a comprehensive network of community cancer centers engaged in advancing clinical research.

Looking ahead, Dr. Zandberg and his team emphasize that these findings warrant further exploration into combining cetuximab with the more potent, currently approved PD-1 inhibitors for cSCC, such as pembrolizumab and cemiplimab, to fully realize improved therapeutic options. This line of inquiry holds promise not only for cSCC but also for other malignancies in which EGFR-targeting and checkpoint blockade may synergize.

In conclusion, this trial represents a compelling step forward in the quest to extend and improve patient lives in advanced cutaneous squamous cell carcinoma. By integrating mechanistic insight with rigorous clinical evaluation, it opens new avenues for immuno-oncology research and sets the stage for future breakthroughs in cancer immunotherapy.

Subject of Research: Advanced cutaneous squamous cell carcinoma (cSCC) treatment with immunotherapy and targeted therapy combination.

Article Title: A phase II (Alliance A091802) randomized trial of avelumab plus cetuximab vs. avelumab alone in advanced cutaneous squamous cell carcinoma (cSCC).

News Publication Date: 31-May-2025

Web References:

• Journal of Clinical Oncology Article DOI
• American Society of Clinical Oncology (ASCO)

References:

• Alliance A091802 clinical trial (NCT03944941)
• Ferris RL et al., research on cetuximab’s immune effects (PMID: 23444227)

Image Credits: UPMC (Photo of Dan Zandberg, M.D.)

Keywords: cutaneous squamous cell carcinoma, cSCC, immunotherapy, avelumab, cetuximab, EGFR, PD-1/PD-L1 blockade, checkpoint inhibitor, monoclonal antibodies, clinical trial, cancer treatment, immune synergism, cancer immunology

Duavee’s dual action tackles menopausal discomfort while exhibiting biologically significant effects on breast tissue. Postmenopausal women diagnosed with ductal carcinoma in situ (DCIS), a non-invasive breast condition widely regarded as a precursor to invasive breast cancer, participated in the trial. DCIS affects approximately 60,000 women annually in the United States alone, representing a substantial population at risk. This phase 2 trial randomized 141 women across ten clinical sites to receive either Duavee or a placebo during a critical window between diagnosis and surgical intervention.

The scientific rationale behind this study centers on the modulation of hormone receptors in breast tissue. Estrogens influence cellular proliferation, and selective estrogen receptor modulators like bazedoxifene are designed to mitigate estrogen’s unwanted effects in the breast while providing beneficial effects elsewhere in the body, such as bone preservation. By combining these agents, Duavee offers a nuanced hormonal environment that was observed to reduce markers indicative of cellular proliferation in breast tissue samples, which are highly predictive of the risk of malignant transformation.

According to Dr. Swati Kulkarni, the lead investigator and a professor of breast surgery at Northwestern University Feinberg School of Medicine, the reduction in cell growth rates observed in the Duavee-treated group is a promising biomarker change indicative of hindered cancer progression pathways. This represents a significant breakthrough as current medications for breast cancer prevention often involve considerable side effects that lead many women to forego prophylactic treatment.

Critically, Duavee’s tolerability profile in this trial appeared favorable. Unlike other hormone-based preventive therapies known for inducing menopausal symptom exacerbation or other systemic side effects, participants receiving Duavee did not report a decline in quality of life. This tolerability could lead to improved adherence and acceptance among women facing the challenge of balancing menopausal management with breast cancer risk reduction.

The target population for this intervention encompasses women with a history of high-risk breast lesions, including atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and lobular carcinoma in situ (LCIS), as well as prior diagnoses of DCIS. These conditions elevate the lifetime risk of invasive breast cancer substantially. Women in this demographic group typically have limited options for hormone therapy during menopause due to concerns about triggering cancerous changes, making Duavee a potentially valuable therapeutic alternative.

The mechanism by which Duavee affects breast tissue involves selective modulation at the estrogen receptor level. Conjugated estrogens provide hormone replacement to alleviate menopausal symptoms, while bazedoxifene acts as an estrogen receptor antagonist specifically in breast and uterine tissue, preventing potential proliferative effects. This complex interplay may disrupt the estrogen-driven pathways responsible for cellular overgrowth, thereby curbing neoplastic progression without compromising systemic estrogen benefits.

This trial’s methodology included administering Duavee or placebo for approximately four weeks, a relatively brief preoperative period allowing precise examination of acute biological effects on breast tissue sampled during surgery. Despite the short duration, the significant decrease in cell proliferation markers underscores a robust biological response, suggesting the potential for even greater benefits with extended therapy, pending future studies.

While these results are compelling, Dr. Kulkarni emphasizes the necessity for larger scale trials with extended follow-up to validate long-term efficacy and safety before recommending Duavee as a standard preventive therapy. The existing FDA approval and widespread clinical availability of Duavee, however, expedite the potential translational impact should future research corroborate these findings.

The broader implications of this research are profound, as it bridges menopausal symptom management and cancer prevention—two domains often treated disparately despite their clinical intersection. The availability of a well-tolerated, dual-purpose medication could revolutionize the approach to care in a vulnerable demographic of postmenopausal women at elevated breast cancer risk.

This study also exemplifies the value of repurposing existing drugs with well-characterized safety profiles, potentially accelerating access to new clinical applications without the lengthy drug development timelines typically required. Such strategies are especially important in oncology, where prevention remains a critical yet underutilized avenue.

In summary, the Northwestern-led clinical trial presents a promising new frontier in breast cancer prevention. Duavee’s ability to slow cellular proliferation in DCIS lesions, coupled with its menopausal symptom relief and favorable side effect profile, highlights its potential as a transformative option. As more comprehensive data emerges, this therapy may become a cornerstone in reducing invasive breast cancer incidence among high-risk postmenopausal women, ultimately improving both longevity and quality of life.

Subject of Research: The investigation into Duavee’s effectiveness in preventing invasive breast cancer progression in postmenopausal women with DCIS.

Article Title: Common Menopause Drug Duavee Shows Potential to Prevent Invasive Breast Cancer in High-Risk Women

News Publication Date: June 1, 2025

Web References:

• Northwestern Medicine Faculty Profile: Dr. Swati Kulkarni
• Clinical Trial Registration: NCT02694809
• ASCO Annual Meeting Presentation Details: ASCO 2025 Meeting
• Breast Cancer Research Foundation on DCIS: About DCIS

Keywords: Breast cancer, DCIS, menopausal symptoms, hormone therapy, conjugated estrogens, bazedoxifene, hormone receptor modulation, cancer prevention, selective estrogen receptor modulator, postmenopausal women, cell proliferation, hormonal biology.

One of the standout studies introduces an online genetic testing platform tailored for patients diagnosed with young-onset colorectal cancer (YOCRC), a demographic identified by cancer onset before the age of 50. Typically, universal germline testing (UGT)—a method to detect hereditary cancer risk—is constrained by resource-intensive demands on physicians and genetic counselors, limiting widespread application. The platform, developed under the guidance of researchers Julie Moskowitz and Y. Nancy You, M.D., revolutionizes this process by enabling patients to independently engage with educational materials, provide informed consent, and initiate genetic testing entirely on their own. The initial pilot involving 160 YOCRC patients revealed a remarkable 63% platform engagement rate, with 89% of these participants completing the testing. Notably, the vast majority of patients navigated the testing process without professional intervention, underscoring the platform’s potential to democratize access to genetic risk assessment.

Parallel to these advancements in genetic counseling, another pioneering investigation centers on ALLO-316, a first-in-human chimeric antigen receptor (CAR) T cell therapy targeting clear cell renal cell carcinoma (ccRCC). This novel treatment is designed to identify and eliminate tumor cells expressing CD70, a protein abundantly present in ccRCC tissues. Led by Samer Srour, M.B.Ch.B., the TRAVERSE study enrolls patients who have exhausted conventional therapies such as checkpoint inhibitors and tyrosine kinase inhibitors. Early data from 44 participants reveal a 33% confirmed objective response among those with tumors richly expressing CD70, accompanied by manageable toxicities including cytokine release syndrome without evidence of graft-versus-host disease. These promising outcomes suggest that ALLO-316 may herald a new therapeutic frontier for metastatic renal cancer, a disease historically resistant to treatment.

Addressing hematologic malignancies, a Phase II clinical trial spearheaded by Guillermo Montalban-Bravo, M.D., explores a potent triplet regimen for higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML), diseases often associated with progression to acute myeloid leukemia (AML). This novel therapeutic approach alternates administration of cladribine with low-dose cytarabine and venetoclax, followed by cycles of azacitidine combined with venetoclax. Preliminary efficacy data reveal overall response rates of 43% in relapsed or refractory patients and an impressive 72% in newly diagnosed cases. Median overall survival was not reached in newly diagnosed patients, indicating durable responses, whereas relapsed patients showed a median survival of 5.8 months. These findings rejuvenate hope for patients with these challenging myeloid disorders by demonstrating the regimen’s safety and therapeutic activity.

Another front in cancer biology is illuminated through spatial transcriptomics in leiomyosarcoma (LMS), a rare but aggressive type of soft tissue sarcoma arising from smooth muscle cells. Ryan Denu, M.D., Ph.D., and collaborators deployed advanced spatial gene expression profiling on over 300 tissue cores from more than 120 patients, including matched primary and metastatic tumor samples. This high-resolution molecular mapping uncovered two novel LMS subtypes distinguished by unique cellular compositions—one predominantly mesenchymal (MES), and the other rich in smooth muscle cell (SMC) markers. Remarkably, the MES subtype demonstrated a more immunosuppressive tumor microenvironment, suggesting potential differences in prognosis and therapeutic vulnerability. Such insights emphasize how integrating spatial genomics can unravel tumor heterogeneity and identify actionable biomarkers in rare cancers.

Immunotherapy’s transformative potential is further exemplified in a study targeting aggressive variant prostate cancer (AVPC), a fiercely progressive form characterized by rapid growth and poor survival. Ana Aparicio, M.D., led a Phase II randomized clinical trial assessing the addition of the anti-PD-1 antibody cetrelimab to a chemotherapy backbone of carboplatin and cabazitaxel, with subsequent maintenance therapy using PARP inhibitor niraparib. Among 60 patients, the cohort receiving cetrelimab achieved a median progression-free survival of 5.6 months compared to just 3.4 months in controls, alongside an extension of median overall survival from 10.2 months to 24.3 months. These compelling results underscore how layering immunotherapy onto chemotherapy and targeted maintenance may extend life for men with AVPC, highlighting the urgent importance of predictive biomarkers to fine-tune patient selection.

Beyond these featured investigations, MD Anderson researchers will also present nine rapid oral abstracts covering critical areas such as non-small cell lung cancer (NSCLC), myelodysplastic syndromes, and novel inhibitors targeting mutated metabolic enzymes. For instance, Tina Cascone, M.D., Ph.D., will update findings from CheckMate 77T, a pivotal study evaluating perioperative nivolumab versus placebo in resectable NSCLC, integrating survival data with biomarker analyses that could optimize immunotherapy application. Meanwhile, Naval Daver, M.D., will report on macrophage checkpoint blockade via Clever-1 inhibition combined with azacitidine in myelodysplastic syndrome, illuminating novel immune targets within the bone marrow microenvironment.

Exciting preclinical and early clinical data also emerge from a Phase I/II study of VLS-1488, an oral inhibitor of kinesin family member KIF18A examined in advanced solid tumors, presented by Ecaterina Elena Dumbrava, M.D. KIF18A plays a key role in mitotic spindle dynamics, and its inhibition offers a promising anti-proliferative strategy in oncology. Additionally, in the COMMANDS trial, Guillermo Garcia-Manero, M.D., will share long-term survival and transfusion independence outcomes in myelodysplastic syndrome patients treated with luspatercept compared with epoetin alfa, potentially refining approaches to anemia management in this patient population.

Further advances come from Jordi Rodon Ahnert, M.D., Ph.D., who will present data on HMPL-306, an inhibitor targeting mutant isocitrate dehydrogenase enzymes (IDH1/2) across solid tumors, including gliomas. Given the oncogenic role of IDH mutations altering cellular metabolism and epigenetics, HMPL-306 represents a tailored approach to disrupt cancer cell survival pathways. Moreover, Alexander Dean Sherry, M.D., will discuss patterns of overall survival and quality of life benefits noted in recent Phase III oncology trials, contributing to evolving standards of care.

Dietary intervention trials also feature notably, with Yufan Qiu, M.D., Ph.D., leading the DIET study—exploring high fiber diets alongside immune checkpoint blockade in melanoma. The study probes how gut microbiota and nutrition might synergize with immunotherapy to enhance anti-tumor responses, reflecting a burgeoning intersection between lifestyle factors and cancer treatment efficacy.

In hematologic malignancies, Michael Wang, M.D., will present data from the SYMPATICO study examining first-line therapy with ibrutinib plus venetoclax in mantle cell lymphoma patients, including older adults and those harboring TP53 mutations, populations traditionally challenged by limited treatment options. Lastly, Vicente Valero, M.D., will reveal findings from a randomized Phase III breast cancer trial integrating carboplatin into standard chemotherapy regimens for triple-negative breast cancer (TNBC), a subtype notorious for its aggressive clinical course.

Taken together, this robust research portfolio epitomizes the dynamic evolution of cancer science, blending molecular innovation with clinical application to confront challenging malignancies. MD Anderson’s contributions at ASCO 2025 stand to reshape therapeutic paradigms, enhance personalized medicine, and ultimately improve patient survival and quality of life in oncology worldwide.

Subject of Research: Cancer research focusing on immunotherapy, targeted therapy, genetic testing, hematologic malignancies, and rare/aggressive tumor types.

Article Title: Transformative Advances in Cancer Therapy and Diagnostics: Highlights from MD Anderson’s 2025 ASCO Presentations

News Publication Date: May 22, 2025

Web References:

• https://meetings.asco.org/abstracts-presentations/243531
• https://meetings.asco.org/abstracts-presentations/243580
• https://meetings.asco.org/abstracts-presentations/246397
• https://meetings.asco.org/abstracts-presentations/248150
• https://meetings.asco.org/abstracts-presentations/243840
• https://mdanderson.org/ASCO

Keywords: Immunotherapy, CAR T cell therapy, young-onset colorectal cancer, genetic testing, myelodysplastic syndromes, leiomyosarcoma, prostate cancer, targeted therapy, spatial transcriptomics, ASCO 2025

Among the most compelling studies featured is a large-scale retrospective analysis evaluating the safety of rechallenging metastatic breast cancer patients with trastuzumab-deruxtecan (T-DXd) following episodes of low-grade interstitial lung disease (ILD). T-DXd, an antibody-drug conjugate approved for HER2-positive and HER2-low breast cancers, entails a rare but significant risk of ILD. This study of 712 patients provides robust real-world evidence that carefully managed rechallenge post-ILD resolution is feasible and can confer substantial clinical benefit. Importantly, steroid administration accelerated radiographic ILD improvement, underscoring timely immunomodulatory interventions to mitigate pulmonary toxicity.

City of Hope researchers meticulously gathered detailed data including patient demographics, T-DXd dosing schedules, steroid use, imaging results, and outcomes from rechallenge protocols. Approximately 9% of treated patients developed ILD, with 47 individuals undergoing drug rechallenge primarily after grade 1 (asymptomatic) ILD. Notably, the recurrence of ILD was predominantly low-grade, with no fatal-grade 5 events recorded. Following rechallenge, patients maintained therapy for a median duration exceeding seven months, suggesting durable benefit despite initial pulmonary complications. These findings provide a critical evidence base to inform clinical decision-making in managing T-DXd-associated ILD.

Shifting focus to genitourinary oncology, City of Hope investigators revealed novel insights into the genomic evolution of renal cell carcinoma (RCC) and its recurrence patterns. Despite curative-intent nephrectomy, about one-fifth of RCC patients experience relapse, posing a clinical challenge. Through precision medicine approaches, the team analyzed pretreatment tumor tissue from 754 patients enrolled in the IMmotion010 Phase 3 trial, which assessed the adjuvant efficacy of the monoclonal antibody atezolizumab. While the trial overall did not demonstrate prevention of disease recurrence, genomic profiling delineated molecular subgroups, particularly those with high KIM-1 biomarker expression and enriched tumor effector (Teff) immune cells, who exhibited prolonged disease-free survival with atezolizumab.

This integrative genomic and transcriptomic profiling illuminates the heterogeneity underlying RCC recurrence and response to immunotherapy. Cluster 6 tumors, characterized by stromal and proliferative signatures, represented a distinct subset deriving benefit from adjuvant checkpoint inhibition. Furthermore, longitudinal analysis through whole-transcriptome sequencing at baseline and recurrence revealed dynamic genomic shifts, offering mechanistic explanations for disease progression. These discoveries pave the way for refined biomarker-driven patient selection, enabling personalized immunotherapeutic strategies that may effectively delay or prevent relapse.

In colorectal cancer, a notoriously immunoresistant malignancy due to prevalent microsatellite stability (MSS), City of Hope’s Phase 2 trial of dual checkpoint inhibition showcases encouraging preliminary results. The combination of Vilastobart (XTX101), an investigational immune checkpoint modulator, with atezolizumab demonstrated tumor shrinkage in patients with advanced MSS colorectal cancer—a group traditionally unresponsive to immunotherapy. Approximately 27% of patients without hepatic metastases achieved partial responses, accompanied by notable reductions in circulating tumor DNA levels, bolstering evidence of anti-tumor activity.

This clinical evaluation, involving heavily pretreated patients, advances the frontier of immuno-oncology by overcoming established resistance mechanisms. The favorable safety profile, marked by low occurrences of severe immune complications and minimal treatment discontinuations, further substantiates the regimen’s potential. Vilastobart’s development by Xilio Therapeutics, co-founded by City of Hope scientist Dr. John Williams, exemplifies translational innovation bridging scientific discovery to clinical application. These data may herald a new era of combinatorial immunotherapies tailored for colorectal cancer subsets.

Turning attention to prostate cancer, a comprehensive observational study led by Dr. Alan H. Bryce leveraged extensive real-world data comprising over 68 million U.S. Medicare and Medicaid beneficiaries. This investigation scrutinized cardiovascular outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients treated with either abiraterone acetate or enzalutamide, two primary androgen-targeting agents. Findings reaffirmed clinical trial signals that abiraterone acetate is associated with a significantly elevated risk of cardiovascular events—including myocardial infarction, stroke, and arrhythmias—compared to enzalutamide, especially in patients without prior chemotherapy.

Strikingly, the risk of all-cause mortality was also heightened in the abiraterone cohort regardless of cardiovascular disease history. These real-world insights emphasize the need for vigilant cardiovascular risk stratification and therapeutic selection in this vulnerable population. By integrating large-scale epidemiological data, the study transcends the limitations of controlled clinical trial environments, offering pragmatic guidance for optimizing treatment algorithms that balance oncologic efficacy with cardiovascular safety.

Collectively, City of Hope’s multifaceted research portfolio presented at ASCO 2025 underscores the institution’s leadership in pioneering personalized oncology solutions rooted in rigorous science and clinical pragmatism. Their work exemplifies how combining molecular diagnostics, real-world evidence, and innovative trial designs accelerates the translation of cutting-edge therapies to patient benefit. As the oncology community converges in Chicago and online, these findings promise to reshape therapeutic landscapes, inspire new collaborations, and invigorate efforts to enhance survival and quality of life for cancer patients worldwide.

City of Hope’s ongoing commitment encompasses not only breakthrough treatment modalities but also the integration of supportive care interventions aimed at reducing cancer risk and improving survivorship outcomes. By embracing a holistic research agenda that spans breast, kidney, colorectal, and prostate cancers, the institution advances the broader mission of transforming hope into reality through science-driven innovation. The upcoming ASCO presentations will undoubtedly catalyze further advancements and highlight the critical role of multidisciplinary expertise in confronting cancer’s complexities.

As oncology continues to evolve at a rapid pace, real-world data, sophisticated genomics, and novel biologic agents are at the forefront of redefining standards of care. City of Hope’s research initiatives exemplify how harnessing these tools can generate actionable insights, leading to safer, more effective, and increasingly individualized treatment protocols. The 2025 ASCO Annual Meeting will serve as a dynamic platform to disseminate these achievements, engage global experts, and foster the collective progress necessary to conquer cancer’s challenges in the decades ahead.

Subject of Research: Novel cancer treatment approaches, targeted therapies, and supportive care interventions focusing on breast, genitourinary, and gastrointestinal cancers.

Article Title: City of Hope Unveils Groundbreaking Cancer Therapies and Precision Medicine Insights Ahead of 2025 ASCO Annual Meeting

News Publication Date: Not explicitly stated; derived from event date (May 30–June 3, 2025)

Web References:

• ASCO Annual Meeting: https://meetings.asco.org/2025-asco-annual-meeting/
• Clinical trials: NCT03024996 (IMmotion010), NCT04896697

References: Information derived from City of Hope press release and abstracts listed for the 2025 ASCO Annual Meeting.

Image Credits: City of Hope

Keywords: Breast cancer, renal cell carcinoma, colorectal cancer, prostate cancer, trastuzumab-deruxtecan, atezolizumab, Vilastobart, immune checkpoint inhibitors, real-world data, cancer genomics, cardiovascular safety, metastatic cancer

The theme for this year’s ASCO assembly, “Driving Knowledge to Action. Building a Better Future,” underscores the critical nexus between cutting-edge research and patient-centered clinical application. City of Hope’s delegation is poised to contribute robust data sets and innovative research paradigms that spotlight precision oncology, novel therapeutic agents, and advanced management approaches for various malignancies including breast, pancreatic, colorectal, prostate, kidney, and hematologic cancers. Moreover, the emphasis on integrative and supportive care, such as palliative interventions, marks a progressive step towards holistic cancer treatment pathways that prioritize quality of life alongside survival metrics.

Central to City of Hope’s presentations are several key oral abstract and clinical symposium sessions that dissect tumor biology and therapeutic resistance in high-risk renal cell carcinoma. The IMmotion010 study, a randomized phase 3 trial exploring adjuvant atezolizumab versus placebo, will unveil comprehensive genomic characterizations of baseline and post-progression tumors. This analysis promises to elucidate mechanisms of immune evasion and tumor evolution, potentially guiding biomarker-driven treatment algorithms in kidney cancer. Leading this discourse is Dr. Sumanta Kumar Pal, a seasoned medical oncologist with extensive expertise in therapeutic research at City of Hope.

Complementing the genomic insights, City of Hope also emphasizes symptom science and palliative care, acknowledging the indispensable role these disciplines play in oncology. Dr. Tanyanika Phillips will chair a session focusing on the management of cancer-related symptoms and the integration of palliative care principles within standard oncology practice. This aligns with the growing recognition that addressing treatment side effects and symptom burden is fundamental to enhancing patient outcomes and curbing healthcare costs.

Dr. Heather Hampel’s involvement as chair and panelist in a session dedicated to hereditary cancer demonstrates City of Hope’s commitment to genetic risk stratification and precision prevention. By delving deeper into hereditary cancer risk and its clinical repercussions, the session will underscore advances in genetic counseling and germline testing that can personalize cancer surveillance and prophylactic strategies.

Rapid oral abstract sessions will highlight groundbreaking work in breast cancer therapy and hematologic malignancies. The investigation led by Dr. Hope S. Rugo into treatment rechallenge following trastuzumab-deruxtecan-related interstitial lung disease addresses a critical safety and efficacy question in metastatic breast cancer management. Understanding how to safely reintroduce this potent antibody-drug conjugate after pulmonary toxicity could expand therapeutic options for patients with resistant disease.

In leukemia research, Dr. Ibrahim T. Aldoss presents a post hoc analysis from the Phase 3 PhALLCON trial regarding minimal residual disease (MRD) negativity after induction therapy. MRD status serves as a highly sensitive biomarker predictive of relapse and survival, and optimizing treatment to achieve MRD negativity is a paramount goal in acute leukemia management. These findings can expedite the adoption of MRD-guided therapeutic decision-making.

Innovations in myeloma treatment will be critically discussed through City of Hope’s participation as a discussant in sessions exploring novel therapeutic avenues targeting plasma cell dyscrasias. Dr. Amrita Krishnan’s expertise enhances the dialogue surrounding emerging regimens and biomarker-driven interventions aimed at improving long-term disease control and patient quality of life in multiple myeloma.

Educational sessions curated by City of Hope further underscore emerging challenges in oncology. Dr. Hope S. Rugo’s presentation on managing endocrine toxicities serves to equip oncologists with best practices for mitigating adverse effects related to novel breast cancer therapies. This is pivotal as new agents with complex side effect profiles enter clinical use, requiring nuanced management strategies to maintain treatment adherence.

Pediatric oncology survivors’ morbidity reduction is addressed in a session led by Dr. Saro H. Armenian, who advocates for personalized intervention approaches. This focus highlights survivorship care as a critical extension of cancer therapy, addressing long-term consequences of childhood cancer treatment through tailored risk assessment and supportive care techniques.

Integrative oncology is also represented, with Dr. Krisstina Gowin presenting evidence-based guidelines for the management of cancer-associated pain, fatigue, and depression. By operationalizing ASCO’s supportive care guidelines into real-world practice, these sessions promote holistic, patient-centered care models that integrate conventional and complementary modalities.

Poster presentations extend the scope of City of Hope’s research portfolio, showcasing innovative clinical trial data across metastatic breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, and genitourinary malignancies. Notably, the NAPOLI 3 Phase 3 trial final overall survival analysis in metastatic pancreatic cancer, presented by Dr. Vincent Chung, offers fresh perspectives on treatment efficacy and long-term survival characteristics. Similarly, evaluations of novel immunotherapies and combinatorial regimens in kidney and prostate cancers provide important insights into optimizing sequencing and combination strategies.

Recognition of City of Hope faculty members such as Drs. Lorna Rodriguez-Rodriguez and Stacy W. Gray, who were inducted as fellows of the American Society of Clinical Oncology (FASCO), reflects the institution’s dedication to leadership in oncology research, education, and clinical excellence. This honor acknowledges their pivotal roles in fostering innovation and advancing standards of care to conquer cancer effectively.

City of Hope’s integrated research-to-practice model, underscored by its NCI-designated comprehensive cancer center, continues to influence oncology globally. The institution’s contributions at the 2025 ASCO Annual Meeting epitomize a mission-driven commitment to transforming complex cancer data into actionable clinical applications that improve patient survival and wellbeing. By converging basic science, translational research, and clinical expertise, City of Hope underscores the future of oncology—a future where knowledge unequivocally drives transformative cancer care.

As oncology confronts the challenges of heterogeneity, resistance mechanisms, and survivorship complexities, City of Hope’s broad research landscape—from molecular tumor characterization to supportive care innovation—foreshadows a new horizon in personalized and effective cancer management worldwide.

Subject of Research: Oncology research and clinical advancements across multiple cancer types, including renal cell carcinoma, breast cancer, pancreatic cancer, colorectal cancer, prostate cancer, kidney cancer, blood cancers, and supportive care modalities.

Article Title: City of Hope Unveils Pioneering Oncology Research at 2025 ASCO Annual Meeting

News Publication Date: Not specified in the provided content

Web References:

• https://meetings.asco.org/2025-asco-annual-meeting
• https://www.cityofhope.org/

References: Not explicitly provided in the content

Image Credits: Not provided

Keywords: Oncology, Cancer Research, Precision Medicine, Immunotherapy, Hematologic Malignancies, Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Clinical Trials, Supportive Care, Palliative Care